Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,529.50
Bid: 1,531.50
Ask: 1,532.00
Change: 3.50 (0.23%)
Spread: 0.50 (0.033%)
Open: 1,537.00
High: 1,541.50
Low: 1,523.00
Prev. Close: 1,526.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Rising Oil Majors Help Offset Sinking Glaxo

Wed, 03rd Feb 2021 16:58

(Alliance News) - It was a mixed day in London on Wednesday, with the FTSE 100 fizzling in afternoon trade as pharma giant GlaxoSmithKline took a dive.

The FTSE 100 index closed off 8.83 points or 0.1%, at 6,507.82, despite gaining as much as 0.9% in morning trading.

The FTSE 250 ended up 62.23 points, or 0.3%, at 20,752.44. The AIM All-Share closed up 9.99 points, or 0.8%, at 1,198.95.

The Cboe UK 100 ended down 0.2% at 646.49, the Cboe UK 250 closed up 0.2% at 18,286.10, and the Cboe Small Companies ended up 1.0% at 12,325.51.

In Paris, the CAC 40 ended marginally lower, while the DAX 30 in Frankfurt advanced 0.7%.

Glaxo lost 6.3%, the worst performer in the blue chip index, after it said adjusted earnings per share fell in 2020, and it expects further decline in the year ahead.

Revenue for 2020 rose 1.0% to GBP34.10 billion from GBP33.75 billion in 2019, with pretax profit growing 12% to GBP6.97 billion from GBP6.22 billion. Consensus had seen Glaxo posting revenue of GBP34.02 billion.

Adjusted earnings per share fell 6% to 115.9 pence, or a 4% decline at constant exchange rates. For 2021, Glaxo expects a "mid to high-single digit percent" decline in adjusted earnings per share at constant currencies.

SpreadEx analyst Connor Campbell noted this is higher than the 3% drop expected by analysts, explaining the drop in share price.

The firm expects healthcare systems and consumer trends will approach normality in the second half of this year, with turnover expected to show flat to low-single digit growth for the Pharmaceuticals and Vaccines businesses and low to mid-single digit growth for Consumer Healthcare.

The firm added it is on track for separation into new standalone Biopharma and Consumer Healthcare companies in 2022.

Separately, Glaxo said it will collaborate with German biopharmaceutical company CureVac to develop next generation mRNA vaccines for Covid-19, with the potential to address multiple emerging variants in one vaccine.

Helping to combat the GSK drop, and keeping the FTSE 100 flat, was London's oil majors rising on swelling oil prices.

Brent oil was quoted at USD58.64 a barrel at the London close, up from USD57.58 at the close Tuesday.

ThinkMarkets analyst Fawad Razaqzada said: "Following three weeks of consolidation, crude oil prices have surged further higher this week. At the time of writing, they were holding near their weekly highs amid expectations of rebounding demand while ongoing OPEC+ supply cuts are also helping to keep the market not too far from being balanced.

"But the rally is unlikely to last too long, in my view. Normal travel is unlikely to start for some time yet, which means the potential upside could be limited from here as the rebound in demand is going to be slow. Also, as prices rise and demand returns, the OPEC will be easing its supply cuts, while shale oil is likely to ramp up production at the same time. Therefore, I can’t see oil prices climbing significantly higher from these levels, although for the time being the path of least resistance remains to the upside."

IG Chief Market Analyst Chris Beauchamp added: "Both BP and Shell have staged a rally today, as the market digests the former's earnings and prepares for the latter. Shell is likely to say broadly the same things as its FTSE 100 peer, namely that it is putting an annus horribilis firmly behind it, and with demand still rising and oil prices on the up it looks like oil majors around the globe have good reason to be cautiously confident."

On Tuesday, BP reported a swing to an annual loss following a tumultuous year in which the global oil and gas industry faced severe challenges.

For 2020, BP swung to a replacement cost loss of USD18.10 billion from an RC profit of USD3.52 billion in 2019 on revenue of USD183.50 billion, down 35% from USD282.62 billion.

For Shell tomorrow, company-compiled consensus sees adjusted earnings at USD5.05 billion for 2020, down 69% on the USD16.46 billion reported for 2019. Adjusted earnings per share are also seen falling 69%, to USD0.64 from USD2.04 the year before.

Analysts consensus has the company reporting lower cash flow from operating activities for 2020. This is expected to be down at USD34.24 billion from USD42.18 billion a year prior.

Shell 'A' shares advanced 0.9% Wednesday, while the 'B' shares rose 1.3%. BP gained 1.3%.

Also in the green, Vodafone ended the FTSE 100's best performer, up 5.9%, after the telecommunications firm said it returned to organic service revenue growth in its third-quarter, helped by a much stronger showing in Germany.

Total revenue in the quarter ended December 31 fell 4.7% to EUR11.20 billion from EUR11.75 billion a year earlier. The organic figure - which strips out the effects M&A activity and currency movements - was 0.4%.

Vodafone generates the bulk of its cash from service revenue, which includes monthly access charges, airtime usage and roaming. In the third quarter ended December, service revenue rose 0.4% on an organic basis. The organic service revenue figure is one that is closely eyed by analysts.

In Germany alone, service revenue rose 1.0% year-on-year on both an organic and reported basis to EUR2.91 billion.

Aviva ended up 3.7% after Morgan Stanley upgraded the blue-chip insurer to Overweight from Equal Weight.

Taylor Wimpey and Persimmon gained 0.9% and 1.5% respectively after Barclays upgraded both UK housebuilders to Overweight from Equal Weight.

Schroders added 1.0% after UBS upped the wealth manager to Buy from Neutral.

The pound was quoted at USD1.3651 at the London equities close, up from USD1.3644 at the close Tuesday.

In the US, Wall Street was muted at the London equities close. The DJIA was 0.2% lower, while both the S&P 500 index and the Nasdaq Composite were up 0.1%.

IG's Beauchamp believes the afternoon data in the US has left investors buying into a 'good news is bad news' thesis.

He said: "The February rally in equities has been deflated somewhat this afternoon, at least in the US, where the bounce from Friday's lows has encountered its first real challenge after breezing higher for 48 hours. Undoubtedly some of the blame will get pinned on today's ADP and ISM numbers, both of which came in stronger than anticipated, and in the case of the payroll report much stronger, with the argument being better data will strengthen the hands of the fiscal hawks on Capitol Hill and give them more firepower in their attempts to water down any Biden stimulus package."

The ISM Services PMI rose to 58.7 in January from 57.7 in December, while US private sector employment increased by 174,000 jobs in January, recovering from a downwardly revised 78,000 jobs in December. The latest figure beat market forecasts, cited by FXStreet, for an increase of 49,000 jobs.

The euro stood at USD1.2022 at the European equities close, down from USD1.2029 late Tuesday. Against the yen, the dollar was trading at JPY105.05, unchanged from late Tuesday.

Gold was quoted at USD1,835.90 an ounce at the London equities close, lower against USD1,837.20 late Tuesday.

In the economic calendar on Thursday there is a UK Markit construction PMI reading at 0930 GMT, followed by eurozone retail sales at 1000 GMT and US initial jobless claims at 1330 GMT.

The focus, however, will remain on the the Bank of England's latest monetary policy decision, alongside the release of the Monetary Policy Committee meeting minutes and the quarterly Monetary Policy Report, at midday on Thursday. A press conference will follow at 1300 GMT.

Analysts largely expect the central bank to stand pat on policy this week despite a recent surge in coronavirus cases, with focus around the debate over negative interest rates.

The Bank Rate, the UK's key interest rate, currently lies at a record low 0.10%, cut to that level back in March last year as the pandemic first hit.

A busy UK corporate calendar on Thursday is headlined by oil major Shell's annual results, alongside annual results from consumer goods giant Unilever, half-year results from housebuilder Barratt Developments and a third quarter update from BT Group.

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
9 Oct 2023 07:42

LONDON BRIEFING: Metro Bank secures deal to shore up finances

(Alliance News) - Stocks in London are set to open higher on Monday as interest rate expectations held steady despite Friday's bumper US nonfarm payrolls report.

Read more
9 Oct 2023 07:20

GSK inks deal to promote shingles vaccine in China

(Sharecast News) - GSK has entered into a new exclusive vaccine partnership in China that will extend the availability of its shingle vaccine Shingrix, which will see the UK-listed group generate £2.5bn over the next three years.

Read more
8 Oct 2023 11:36

Sunday newspaper round-up: Renewi, Metro Bank, New homes

(Sharecast News) - Some of Renewi's major shareholders are divided as to whether the recycling company should engage with Australian suitor Macquarie. One major shareholder has told Renewi's board that it should not until Macquarie raised its £636m bid, but another top ten shareholder told The Sunday Times that it should talk to the Australian outfit anyways. Macquarie has until 26 October to make a firm offer. - The Sunday Times

Read more
6 Oct 2023 08:17

GSK raises £885.6m from Haleon share sale

(Sharecast News) - GSK said on Friday that it has sold 270m shares in Haleon - the consumer health business it spun off last year - raising around £885.6m.

Read more
6 Oct 2023 07:57

UPDATE: GSK banks GBP886 million from Haleon share sale

(Alliance News) - GSK PLC on Friday said it received GBP885.6 million in gross proceeds from its sale of shares in consumer healthcare spin-off Haleon PLC.

Read more
6 Oct 2023 07:46

LONDON BRIEFING: Wetherspoon swings to profit; UK house prices fall

(Alliance News) - Stocks in London are called to open higher on Friday, as investors eye a key nonfarm payroll reading in the US.

Read more
5 Oct 2023 15:47

UK dividends calendar - next 7 days

Friday 6 October 
Admiral Group PLCdividend payment date
Alfa Financial Software Holdings PLCspecial dividend payment date
Anglo-Eastern Plantations PLCdividend payment date
Blackrock World Mining Trust PLCdividend payment date
Cairn Homes PLCdividend payment date
Dalata Hotel Group PLCdividend payment date
Drax Group PLCdividend payment date
Glanbia PLCdividend payment date
GlobalData PLCdividend payment date
Goodwin PLCdividend payment date
Greggs PLCdividend payment date
Intertek Group PLCdividend payment date
Irish Continental Group PLCdividend payment date
JPMorgan American Investment Trust PLCdividend payment date
JPMorgan Global Growth & Income PLCdividend payment date
Land Securities Group PLCdividend payment date
Personal Assets Trust PLCdividend payment date
Quartix Technologies PLCdividend payment date
Serco Group PLCdividend payment date
Walker Crips Group PLCdividend payment date
Warehouse REIT PLCdividend payment date
Zotefoams PLCdividend payment date
Monday 9 October 
Henderson Smaller Cos Investment Trust PLCdividend payment date
LondonMetric Property PLCdividend payment date
Tuesday 10 October 
LSL Property Services PLCdividend payment date
Wednesday 11 October 
Assura PLCdividend payment date
Rathbones Group PLCdividend payment date
Thursday 12 October 
Blackrock Latin American Investment Trust PLCex-dividend payment date
Breedon Group PLCex-dividend payment date
Diageo PLCdividend payment date
GSK PLCdividend payment date
Howden Joinery Group PLCex-dividend payment date
i3 Energy PLCex-dividend payment date
Invesco Bond Income Plus Ltdex-dividend payment date
JPMorgan Asia Growth & Income PLCex-dividend payment date
JPMorgan Mid Cap Investment Trust PLCex-dividend payment date
Kingfisher PLCex-dividend payment date
MP Evans Group PLCex-dividend payment date
Macfarlane Group PLCdividend payment date
North American Income Trust PLCex-dividend payment date
Oxford Instruments PLCdividend payment date
Persimmon PLCex-dividend payment date
Personal Group Holdings PLCex-dividend payment date
Primary Health Properties PLCex-dividend payment date
Ruffer Investment Co Ltdex-dividend payment date
Senior PLCex-dividend payment date
Spirax-Sarco Engineering PLCex-dividend payment date
Strategic Equity Capital PLCex-dividend payment date
Supermarket Income REIT PLCex-dividend payment date
Taylor Wimpey PLCex-dividend payment date
Tesco PLCex-dividend payment date
TT Electronics PLCdividend payment date
WPP PLCex-dividend payment date
XP Power Ltddividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
3 Oct 2023 18:19

IN BRIEF: GSK's Jemperli approved in UK for endometrial cancer

GSK PLC - London-based pharmaceutical company - On Monday, announces that the UK Medicines & Health Products Regulatory Agency has authorised a new indication for Jemperli, also known as dostarlimab. The drug is used as a treatment for some types of endometrial cancer and an be used to treat patients that have a tumour abnormality called mismatch repair deficient/microsatellite instability-high when the cancer is at an advanced stage when first diagnosed or has returned after previous treatment. It is now authorised to be used together with chemotherapy to slow the progression of these cancers. GSK says it is the first medicine licensed as first line treatment for primary advanced or recurrent endometrial cancer.

Read more
3 Oct 2023 11:59

LONDON MARKET MIDDAY: HSBC and StanChart help FTSE 100 outperform

(Alliance News) - London's FTSE 100 grew in confidence as Tuesday morning progressed, going into the afternoon in the green and outperforming European peers.

Read more
25 Sep 2023 09:13

LONDON BROKER RATINGS: Jefferies raises AstraZeneca to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
25 Sep 2023 08:37

TOP NEWS: GSK's Arexvy vaccine approved for adults over 60 in Japan

(Alliance News) - GSK PLC on Monday said the Japan Ministry of Health, Labour & Welfare has approved Arexvy for adults over 60.

Read more
25 Sep 2023 07:28

GSK's RSV vaccine gets approval in Japan

(Sharecast News) - GSK announced on Monday that its vaccine, Arexvy, has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for preventing respiratory syncytial virus (RSV) disease in adults aged 60 and over.

Read more
19 Sep 2023 09:30

GSK says new HIV PrEP medication authorised by European Commission

(Alliance News) - GSK PLC on Tuesday said the European Commission has authorised ViiV Healthcare's "superior" drug Apretude to reduce the risk of sexually acquired HIV-1 infection.

Read more
18 Sep 2023 09:40

LONDON BROKER RATINGS: Jefferies likes Energean; JPMorgan raises IDS

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
18 Sep 2023 07:57

LONDON BRIEFING: Phoenix Group hails "impressive" first-half

(Alliance News) - Stocks in London are called lower on Monday, as investors focus on the week's upcoming central bank decisions.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.